Literature DB >> 22499021

Human parvovirus B19 surveillance in patients with rash and fever from Belarus.

Marina A Yermalovich1, Judith M Hübschen, Galina V Semeiko, Elena O Samoilovich, Claude P Muller.   

Abstract

Human parvovirus B19 (B19V) infection in immunocompetent patients usually has a mild clinical course, but during pregnancy it can cause serious and even fatal complications in the fetus. The most common clinical presentation of B19V infection is erythema infectiosum and in this case laboratory confirmation is required for differentiation from other exanthematous diseases. Measles and rubella negative sera collected in Belarus between 2005 and 2008 from 906 patients with a rash and fever were screened for B19V infection by ELISA. More than 35% of the samples (322/906) were positive for B19V. The proportion ranged from 10.1% in 2008 to 53.2% in 2006 when an outbreak took place in Minsk city. All B19V outbreaks and cluster cases occurred during the winter-spring period, but sporadic cases were recorded basically throughout the year. The majority of the cases (56.5%) occurred among the 2 till 10 year old children, and 27.3% of the cases were observed in adults between 19 and 53 years. All 104 B19V strains sequenced in the NS1/VP1u region belonged to genotype 1 with a maximal genetic distance of 1.75%. The two phylogenetic clusters reflected the geographic origins of the viruses within the country. Forty-two unique nucleotide mutations as compared to sequences downloaded from GenBank were found in the VP1u and NS1 regions; most of these changes were nonsynonymous. This report highlights the importance of B19V infection in patients with a rash and fever in Belarus.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499021     DOI: 10.1002/jmv.23294

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Measles Virus Infection Among Vaccinated and Unvaccinated Children in Nigeria.

Authors:  Adedayo O Faneye; Johnson A Adeniji; Babatunde A Olusola; Babatunde O Motayo; Grace B Akintunde
Journal:  Viral Immunol       Date:  2015-06-23       Impact factor: 2.257

2.  Comprehensive surveillance data suggest a prominent role of parvovirus B19 infection in Belarus and the presence of a third subtype within subgenotype 1a.

Authors:  Marina A Yermalovich; Alina M Dronina; Galina V Semeiko; Elena O Samoilovich; Vladislav V Khrustalev; Aurelie Sausy; Judith M Hübschen
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

3.  The effects of co-infection with human parvovirus B19 and Plasmodium falciparum on type and degree of anaemia in Ghanaian children.

Authors:  Kwabena Obeng Duedu; Kwamena William Coleman Sagoe; Patrick Ferdinand Ayeh-Kumi; Raymond Bedu Affrim; Theophilus Adiku
Journal:  Asian Pac J Trop Biomed       Date:  2013-02

4.  The seroprevalence of parvovirus B19 infection in pregnant women in Sudan.

Authors:  O Adam; T Makkawi; U Reber; H Kirberg; A M Eis-Hübinger
Journal:  Epidemiol Infect       Date:  2014-03-20       Impact factor: 4.434

5.  Etiology of maculopapular rash in measles and rubella suspected patients from Belarus.

Authors:  Marina A Yermalovich; Galina V Semeiko; Elena O Samoilovich; Ekaterina Y Svirchevskaya; Claude P Muller; Judith M Hübschen
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

6.  Beyond arboviruses: A multicenter study to evaluate differential diagnosis of rash diseases and acute febrile illness cases in Rio de Janeiro, Brazil.

Authors:  Arthur Daniel Rocha Alves; Jéssica Vasques Raposo; Rafaela Moraes Pereira de Sousa; Claudete Aparecida Araújo Cardoso; Pâmela Karla Simões de Freitas Costa; Julienne Martins Araújo; Sabrina Teresinha Alvim Barreiro; Clarisse da Silveira Bressan; Guilherme Amaral Calvet; Rogério Valls de Souza; Patrícia Brasil; Rita de Cássia Nasser Cubel Garcia; Marcelo Alves Pinto; Vanessa Salete de Paula; Luciane Almeida Amado
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.